Ono Pharmaceutical

Update in progress

4528.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Ono Pharmaceutical Co., Ltd. is a global biopharma company that develops, manufactures, and sells medicines and diagnostic reagents for cancer, cardiovascular, metabolic, autoimmune, and CNS diseases. Its portfolio includes cancer therapies such as Opdivo, Kyprolis, Mektovi, Braftovi, and Forxiga, plus treatments for diabetes, heart failure, arrhythmia, osteoporosis, arthritis, and inflammatory conditions. It partners with several firms and is based in Osaka, Japan.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.04; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive